Selected article for: "longitudinal observational study and prospective longitudinal observational study"

Author: Mangion, Kenneth; Morrow, Andrew; Bagot, Catherine; Bayes, Hannah; Blyth, Kevin G; Church, Colin; Corcoran, David; Delles, Christian; Gillespie, Lynsey; Grieve, Douglas; Ho, Antonia; Kean, Sharon; Lang, Ninian N; Lennie, Vera; Lowe, David; Kellman, Peter; Macfarlane, Peter W; McConnachie, Alex; Roditi, Giles; Sykes, Robert; Touyz, Rhian M; Sattar, Naveed; Wereski, Ryan; Wright, Sylvia; Berry, Colin
Title: The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study
  • Cord-id: qmck9pp9
  • Document date: 2020_7_23
  • ID: qmck9pp9
    Snippet: BACKGROUND: COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear. METHODS: This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be
    Document: BACKGROUND: COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear. METHODS: This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation. CONCLUSION: CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute kidney injury: 1, 2, 3, 4, 5, 6, 7
    • absence presence and acute myocarditis: 1
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and liver kidney: 1, 2
    • absence presence and local standard: 1
    • absence presence and long term follow: 1, 2, 3, 4
    • absence presence and lung damage: 1, 2
    • absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • absence presence and lung pathology: 1
    • absence presence and lung perfusion: 1
    • absence presence and lv function: 1
    • absence presence and lv systolic dysfunction: 1
    • acute illness and liver kidney: 1, 2, 3, 4
    • acute illness and liver kidney lung: 1, 2
    • acute illness and liver kidney lung heart: 1
    • acute illness and local standard: 1
    • acute illness and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute illness and low radiation: 1
    • acute illness and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30